Switching Antiviral Medications for the Treatment of HIV

What we are studying

The treatment of HIV infection requires the combination of several medications in order to decrease the amount of virus in the body, improve immune function and delay the progression of the disease. This has generally required patients to take a large number of pills each day, and many experience a loss of effectiveness of their current medication regimen over time or unacceptable side effects. Therefore, it is important to develop new drug regimens. In addition, the combination of drugs into a single tablet reduces the number of pills a patient has to take and makes it more convenient to stick to the prescribed drug regimen. The purpose of this study is to evaluate safety and to determine whether a new combination drug is effective against HIV-1 in subjects on current antiretroviral regimens in virologically suppressed, HIV-1 positive subjects.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • HIV-1 infection
  • Undetectable HIV viral load
  • Currently taking Darunavir (Prezista)

What is involved

  • 12 clinic vistis over 48 weeks
  • Study activities include physical exams; laboratory tests; and questions about any problems you might experience during the study

Contact Information

Study Coordinator
Liby Mosley
Principal Investigator
Dr. Aimee Wilkin

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.